InsiderTrades

Form 4 for NTLA Intellia Therapeutics, Inc.

Accepted 2023-06-22 00:00:00 ET · period of report 2023-06-20 · accession 0001209191-23-039148 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2023-06-22 2023-06-20 NTLA Clark Eliana EVP, Chief Technical Off M - OptEx $12.27 +5,000 50.1K +11% +$61.4K
D 2023-06-22 2023-06-20 NTLA Clark Eliana EVP, Chief Technical Off S - Sale+OE $45.00 -5,000 45.1K -10% -$225.0K
D 2023-06-22 2023-06-20 NTLA Clark Eliana EVP, Chief Technical Off M - OptEx $0.00 -5,000 57.8K -8% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-06-20 M A 5,000 $12.27 50,146 D — —
2 Common Common Stock 2023-06-20 S D 5,000 $45.00 45,146 D — —
3 Derivative Stock Option (right to buy) 2023-06-20 M D 5,000 $0.00 57,750 D $12.27 · — to 2030-02-02 5,000 Common Stock (F2) The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 64,062 shares as of June 20, 2023.